A PHASE 1, RANDOMIZED, OPEN-LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-04965842 ON THE PHARMACOKINETICS OF SINGLE-DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE SUBJECTS
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Abrocitinib (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 29 Jan 2019 Status changed from recruiting to completed.
- 19 Dec 2018 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
- 03 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.